Market research
ABCL Abcellera Biologics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 17.125
- Dividend yield
- Not available
- Beta
- 1.19
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA00288U1066
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 17.125
- Dividend yield
- Not available
- Beta
- 1.19
About
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ABCL discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 31.7.
Based on the above factors, AbCellera Biologics Inc gets an overall score of 1/5.